Table 4.

Each cemiplimab-related adverse event occurred in at least two of the 240 treated patients.

Adverse Event	Any Grade	Grade ≥ 3
Any	75 (31)	22 (9)
Led to cemiplimab discontinuation	16 (7)	12 (5)
Fatigue	21 (9)	4 (2)
Arthralgias/myalgias	17 (7)	2 (1)
Cholestasis/cytolysis/hepatitis	10 (4)	5 (2)
Diarrhea	7 (3)	0
Pruritus	6 (3)	0
Rash	5 (2)	0
Hypothyroidism	5 (2)	0
Renal failure	5 (2)	3 (1)
Hyperthyroidism	4 (2)	0
Lymphopenia	3 (1)	0
Decreased appetite	3 (1)	1 (0.4)
Peripheral neuropathy	3 (1)	0
Anemia	2 (1)	0
Neutropenia	2 (1)	0
Myocarditis	2 (1)	1 (0.4)
Corticotropic insufficiency	2 (1)	0
Colitis	2 (1)	2 (1)
Vomiting	2 (1)	1 (0.4)
Loss of weight	2 (1)	0
Balance disorder	2 (1)	0
Transplant rejection	2 (1)	2 (1)

Results are expressed as number (%).